このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults (FORM-Resp)

Prospective Self-Control Study on the Effects of Short-Term High-Concentration Formaldehyde Exposure on Respiratory Microecology and Inflammatory Markers in Healthy Adults

Formaldehyde exposure is common in some occupational environments, including anatomy laboratories, and may affect respiratory health. However, the early biological changes caused by short-term high-concentration formaldehyde exposure remain unclear.

This prospective self-controlled observational study aims to evaluate the effects of short-term high-concentration formaldehyde exposure on respiratory microecology, inflammatory biomarkers, and acute respiratory symptoms in healthy adults. Participants will be monitored before and after formaldehyde exposure, and changes in airway-related biological indicators will be assessed through biological samples and clinical evaluations.

The findings of this study may provide human evidence for exposure control, ventilation improvement, protective measures, and health risk assessment in environments with formaldehyde exposure.

調査の概要

状態

積極的、募集していない

詳細な説明

This is a prospective self-controlled observational study designed to investigate early respiratory biological responses associated with short-term high-concentration formaldehyde exposure in healthy adults.

Participants will be healthy medical students who enter an anatomy laboratory and experience short-term formaldehyde exposure during anatomy training. Each participant will serve as his or her own control. Biological samples and clinical information will be collected at multiple time points, including before exposure (T0), 6 hours after exposure (T1), and 24 hours after exposure (T2).

The study will evaluate changes in respiratory microecological composition, local inflammatory responses, systemic inflammatory and oxidative stress-related biomarkers, and acute irritation symptoms after formaldehyde exposure. Formaldehyde exposure levels, exposure duration, and protective measures will also be recorded to explore the relationship between exposure intensity and biological responses.

At T0, baseline information, respiratory symptoms, induced sputum samples, peripheral blood samples, and other relevant assessments will be collected. During and after exposure, environmental formaldehyde concentrations and exposure-related information will be monitored. At T1 and T2, repeated assessments will be performed, including symptom evaluation, induced sputum collection, peripheral blood collection, inflammatory biomarker detection, and respiratory microecological analysis.

This study aims to provide human-based evidence regarding early respiratory effects of short-term formaldehyde exposure and may contribute to improving ventilation strategies, occupational protection measures, exposure duration control, and health risk assessment in formaldehyde-exposed environments.

研究の種類

観察的

入学 (推定)

65

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Zhejiang
      • Ningbo、Zhejiang、中国、315211
        • Wang Changlai Building, East Campus, Ningbo University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~35年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Healthy adult medical students who attend anatomy laboratory courses involving short-term formaldehyde exposure will be recruited. Participants will undergo prospective self-controlled observation before and after exposure. Changes in respiratory microbiome composition, airway inflammatory biomarkers, systemic inflammatory and oxidative stress indicators, and acute irritation symptoms after formaldehyde exposure will be evaluated.

説明

Inclusion Criteria:

  • 1: Aged 18-35 years old

    2: The healthy medical students who participated in the anatomy course for the first time had no systematic formaldehyde / formalin occupational or teaching exposure in the past 6 months.

    3: Health examination, and no history of chronic respiratory diseases ( such as asthma, active allergic rhinitis, chronic sinusitis, bronchiectasis, interstitial pulmonary fibrosis, etc. )

    4: There were no acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms in the past 4 weeks.

    5: There was no use of antibiotics, glucocorticoids, bronchodilators, and immunomodulatory drugs in the past 4 weeks.

    6: There was no obvious eye, nose, throat irritation or lower respiratory symptoms at baseline, and was able to cooperate with the completion of three induced sputum, two peripheral blood collections and related follow-up evaluations

    7: Voluntary to participate in and sign a written informed consent.

Exclusion Criteria:

  • 1: Have asthma, COPD, bronchiectasis, interstitial lung disease, chronic sinusitis, active allergic rhinitis or other chronic airway inflammatory diseases

    2: Acute upper respiratory tract infection, fever, COVID-19 or influenza-like symptoms, or active allergies / obvious seasonal allergies occurred in the past 4 weeks

    3: Used antibiotics, systemic or inhaled corticosteroids, bronchodilators, immunomodulatory drugs in the past 4 weeks

    4: Current smoking, use of e-cigarettes or hookah, smoking history in the past six months, or obvious high exposure to second-hand smoke in the past four weeks

    5: Exposure to non-daily formaldehyde, formalin or other strong irritant chemicals in the past 4 weeks

    6: Have a clear history of allergy to formaldehyde or other chemicals, or intolerance to hypertonic saline atomization

    7: Pregnant or lactating women

    8: Severe cardiovascular and cerebrovascular diseases, coagulation dysfunction, recent hemoptysis, severe hypertension, recent ophthalmic surgery, epilepsy requiring drug treatment, severe arrhythmia or other conditions not suitable for induced sputum operation

    9: All follow-ups and biological sample collections could not be completed for personal reasons, or researchers considered it inappropriate to continue participating in the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:RETROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Formaldehyde Exposure Cohort

Healthy adults receiving anatomy laboratory courses were enrolled in this prospective self-controlled observational study. Participants were exposed to short-term formaldehyde released from fixed tissue specimens in the anatomy laboratory and were evaluated before and after exposure.

Short-term high-concentration formaldehyde exposure during anatomy laboratory courses

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in the Shannon Diversity Index of Induced Sputum Microbiota
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The Shannon Diversity Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index evaluates microbial alpha diversity by accounting for both taxon richness and evenness. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater microbial diversity. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

二次結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in the Chao1 Richness Index of Induced Sputum Microbiota
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The Chao1 Richness Index of induced sputum microbiota will be measured using 16S ribosomal ribonucleic acid gene sequencing. The index estimates the number of microbial taxa in a sample. It has a minimum value of 0 and no fixed maximum value, with higher values indicating greater estimated microbial richness. Change from baseline will be calculated as the value at each post-exposure time point minus the baseline value.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
R-Squared Value From Permutational Multivariate Analysis of Variance of Induced Sputum Microbial Community Structure Across Sampling Time Points
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Beta diversity of induced sputum microbiota will be evaluated using principal coordinates analysis and permutational multivariate analysis of variance. The primary reported measure will be the R-squared value from the permutational multivariate analysis of variance, representing the proportion of variation in microbial community structure explained by sampling time. Values range from 0 to 1, with higher values indicating that sampling time explains a greater proportion of variation in microbial community structure.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Induced Sputum Neutrophil Percentage
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage and reported in percentage points.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Neutrophils in Induced Sputum
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of neutrophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of neutrophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Macrophages and Monocytes in Induced Sputum
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of macrophages and monocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of macrophages and monocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Lymphocytes in Induced Sputum
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of lymphocytes in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of lymphocytes. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Eosinophils in Induced Sputum
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of eosinophils in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of eosinophils. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in the Percentage of Bronchial Epithelial Cells in Induced Sputum
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

The percentage of bronchial epithelial cells in induced sputum will be determined by differential cell counting of stained cytospin slides. Values range from 0% to 100%, with higher values indicating a greater proportion of bronchial epithelial cells. Change from baseline will be calculated as the percentage at each post-exposure time point minus the baseline percentage.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 1 Beta Concentration in Induced Sputum Supernatant
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 1 beta concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 6 Concentration in Induced Sputum Supernatant
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 6 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 8 Concentration in Induced Sputum Supernatant
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Interleukin 8 concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration.

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Induced Sputum Supernatant
時間枠:Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Tumor necrosis factor alpha concentration will be measured in induced sputum supernatant. Change from baseline will be calculated as the concentration at each post-exposure time point minus the baseline concentration

Baseline within 48 hours before exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in C-Reactive Protein Concentration in Peripheral Blood
時間枠:Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

C-reactive protein concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Interleukin 6 Concentration in Peripheral Blood
時間枠:Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Interleukin 6 concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Tumor Necrosis Factor Alpha Concentration in Peripheral Blood
時間枠:Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Tumor necrosis factor alpha concentration will be measured in peripheral blood. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Malondialdehyde Concentration in Peripheral Blood
時間枠:Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure

Malondialdehyde concentration will be measured in peripheral blood as a marker of oxidative stress. Change from baseline will be calculated as the concentration 24 hours after exposure minus the baseline concentration.

Baseline within 48 hours before exposure and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Eye Irritation Score Assessed Using a Visual Analog Scale
時間枠:Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Eye irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Nasal Irritation Score Assessed Using a Visual Analog Scale
時間枠:Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Nasal irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Throat Irritation Score Assessed Using a Visual Analog Scale
時間枠:Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Throat irritation will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Cough Score Assessed Using a Visual Analog Scale
時間枠:Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Cough will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure
Change From Baseline in Chest Tightness Score Assessed Using a Visual Analog Scale
時間枠:Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

Chest tightness will be rated by each participant using a visual analog scale ranging from 0 to 10, where 0 indicates no symptoms and 10 indicates the most severe symptoms imaginable. Higher scores indicate greater symptom severity. Change from baseline will be calculated as the score at each post-exposure assessment minus the baseline score.

Baseline within 48 hours before exposure, immediately after exposure, 6 hours plus or minus 1 hour after exposure, and 24 hours plus or minus 1 hour after exposure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Chao Cao、Ningbo University Affiliated First Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月11日

一次修了 (実際)

2026年11月1日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2026年9月14日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 2026-R311-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

The plan for sharing individual participant data (IPD) has not yet been determined. Any future data sharing will be considered in accordance with ethical requirements, participant privacy protection, and institutional policies.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する